Clinical trials: Diabetes Mellitus II
Diabetes Mellitus, Type 2, Overweight and Obesity
Dietary Strategies for Remission of Type 2 Diabetes
In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program)…
- Conditions
- Diabetes Mellitus, Type 2, Overweight and Obesity, Hypertension, Glucose Intolerance
- Trial name
- CARBCOUNT (NCT04943926)
- Testing
- Energy restricted diet, Low carbohydrate high fat diet
- Where
- Norway
- Volunteers
- 600 people
- Sponsor
- University of Bergen
Type II Diabetes
Passive Stretching Versus Electrical Stimulation on Glucose Level, in Elderly With Type II Diabetes
Sixty elderly diabetics (type II) their age ranged from 60-75 years had been divided into two equal groups; group (A) treated by 40-minute passive stretching exercises, while the group (B) treated by 30 minutes electrical…
- Trial name
- NCT06245252
- Testing
- passive stretching for group A, electrical stimulation for group b
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Mona Mohamed Abdelkhalek
Type 1 Diabetes (T1D), Type 2 Diabetes
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care…
- Conditions
- Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus
- Trial name
- PREPARE 4 AID (NCT07011147)
- Testing
- Bionic Pancreas, Routine Care
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus Type II
Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type II
- Trial name
- PUNiDIA (NCT02144948)
- Testing
- e.-coli-nissle
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- GWT-TUD GmbH
Hyperuricemia, Diabetic Nephropathies
Hyperuricemia and Diabetic Nephropathy
The purpose of the study is to detect the effect of treatment of hyperuricemia on eGFR (Estimated Glomerular Filtration Rate) as an objective criterion for assessment of progression of diabetic nephropathy in patients with Type 2…
- Trial name
- NCT04799925
- Testing
- Febuxostat
- Volunteers
- 200 people
- Sponsor
- Assiut University
Type 2 Diabetes Mellitus
Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes.
- Trial name
- TINSALT2D-II (NCT00799643)
- Testing
- Salsalate
- Where
- 21 sites in United States
- Volunteers
- 638 people
- Sponsor
- Joslin Diabetes Center
Type 2 Diabetes Mellitus
Tertiary Prevention in Type II Diabetes Mellitus in Canary Islands Study
Objective: To improve health outcomes of patients with type 2 diabetes mellitus (T2DM) by influencing disease self-management through lifestyle modification and by helping primary care professionals to improve health care…
- Trial name
- INDICA (NCT01657227)
- Testing
- Intervention to patients, Intervention to professionals, Usual care
- Where
- Spain
- Volunteers
- 2,334 people
- Sponsor
- Servicio Canario de Salud
Diabetic Nephropathy, Hypertension
Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.
The purpose of this study is to determine the safety and effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.
- Trial name
- NCT01923597
- Testing
- Green tea extract
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Campinas, Brazil
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Type 1
The GlucoPred Investigation II
Diabetes mellitus type 1 (DM1) is an autoimmune metabolic disease in which the insulin producing cells in the pancreas are destroyed and the subject is left totally dependent of external supply of insulin.
- Trial name
- GPI-II (NCT02595580)
- Testing
- Glucopred
- Where
- 2 sites in Norway
- Volunteers
- 16 people
- Sponsor
- Norwegian University of Science and Technology
Type 2 Diabetes
Determining the Minimal Amount of Exercise to Improve Glycaemic Control
In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide.
- Trial name
- MiniEx (NCT04129268)
- Testing
- Cycle ergometry exercise at 60% VO2max
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Lancaster University
Diabetes Mellitus, Type I Diabetes
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
By 2020, it is estimated that 3.7 million Canadians will have diabetes mellitus, with type 2 diabetes (T2DM) accounting for more than 90% of cases.
- Conditions
- Diabetes Mellitus, Type I Diabetes, Type II Diabetes, Diabetic Peripheral Neuropathy
- Trial name
- AWARE (NCT02127762)
- Testing
- Mindfulness Based Stress Reduction
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- Ottawa Hospital Research Institute
Diabetes Mellitus
Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the safety and efficacy of TAK-559, once daily (QD), combined with glyburide in treating Type 2 Diabetes.
- Trial name
- ORIGAMI (NCT00759720)
- Testing
- TAK-559 and glyburide, Glyburide
- Volunteers
- 447 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Trial name
- SURPRISE (NCT01154244)
- Testing
- HOMA-IR
- Where
- 2 sites in South Korea
- Volunteers
- 1,439 people
- Sponsor
- GlaxoSmithKline
Gastric Cancer
Oncometabolic Surgery
Recently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes…
- Trial name
- KLASS-09 (NCT07437573)
- Testing
- long-limb Roux-en-Y gastrojejunostomy
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Korea University Guro Hospital
Type II Diabetes Mellitus
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.
- Trial name
- NCT01262586
- Testing
- Vildagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria
- Trial name
- NCT01756703
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 43 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 67 people
- Sponsor
- Tanabe Pharma Corporation
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Despite the fact that the majority of the patients with limited disease SCLC will respond very well to the standard treatment, a great proportion will relapse within 12 - 24 months.
- Trial name
- STIMULI (NCT02046733)
- Testing
- Ipilimumab, Nivolumab
- Where
- 61 sites in Australia, Belgium and 6 more
- Volunteers
- 222 people
- Sponsor
- ETOP IBCSG Partners Foundation
Type II; Diabetes
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.
- Trial name
- AZ11040 (NCT02984644)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Healthy, Type 2 Diabetes Mellitus
Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters.
- Trial name
- #6113 (NCT01681693)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco